Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by scarlet1967on Jun 25, 2021 7:31am
188 Views
Post# 33449372

Manager or Global Manager, Pricing and Reimbursement

Manager or Global Manager, Pricing and Reimbursement
This recent job posting is interesting as the applicant will be responsible for developing plans related to reimbursement of current and future drugs in HIV, Oncology and NASH.
 
“Reporting to the Global Commercial Officer, the Global Pricing & Reimbursement Lead will play a critical leadership role in developing, leading and coordinating plans and related core deliverables aimed at building, shaping and expanding access and securing reimbursement for Theratechnologies current and future products in HIV, oncology, and hepatology (NASH). 
Key Responsibilities
Provide immediate support and strategic direction to optimize pricing and expand the reimbursement of products in Europe and other international.
Increase corporate visibility and build alliances with key stakeholders to support the successful reimbursement of Oncology and NASH launch assets in priority countries.
Identify and partner with strategic partners (outside consultants) to achieve optimal outcomes for reimbursement and pricing strategies and local implementation….”
https://www.linkedin.com/jobs/view/2609260708
 
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse